Hannah Cheeseman

List of Publications by Year
in descending order

10	720	932766 10	1372195 10
papers	citations	h-index	g-index

11	11	11	1395
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BMJ, The, 2021, 372, n423.	3.0	56
2	Vaccines for COVID-19. Clinical and Experimental Immunology, 2020, 202, 162-192.	1.1	185
3	Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunology, 2018, 11, 249-256.	2.7	85
4	Broad HIV Epitope Specificity and Viral Inhibition Induced by Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2014, 9, e90378.	1.1	13
5	Safety and Immunogenicity of DNA Prime and Modified Vaccinia Ankara Virus-HIV Subtype C Vaccine Boost in Healthy Adults. Vaccine Journal, 2013, 20, 397-408.	3.2	23
6	A DNA-Based Candidate HIV Vaccine Delivered viaIn VivoElectroporation Induces CD4 Responses toward the Î±4Î²7-Binding V2 Loop of HIV gp120 in Healthy Volunteers. Vaccine Journal, 2012, 19, 1557-1559.	3.2	36
7	A Phase I Double Blind, Placebo-Controlled, Randomized Study of a Multigenic HIV-1 Adenovirus Subtype 35 Vector Vaccine in Healthy Uninfected Adults. PLoS ONE, 2012, 7, e41936.	1.1	74
8	In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers. PLoS ONE, 2011, 6, e19252.	1.1	160
9	Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials. Journal of Immunological Methods, 2011, 370, 43-54.	0.6	14
10	Viral Inhibition Assay: A CD8 T Cell Neutralization Assay for Use in Clinical Trials of HIVâ€1 Vaccine Candidates. Journal of Infectious Diseases, 2010, 201, 720-729.	1.9	74